Plain-English translation of NCT06929936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two drugs—trilaciclib and docetaxel—for people with advanced lung cancer who have already been treated with at least one other therapy. Trilaciclib is a newer medication designed to protect your bone marrow and blood cells during chemotherapy, which may help reduce serious side effects like infections and the need for blood transfusions.
Chemotherapy can seriously damage the cells in bone marrow that make blood cells, leading to infections and other complications. This medication is being tested to see whether giving it before chemotherapy can prevent these damaging side effects and make treatment safer and more tolerable.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination over 4 treatment cycles. Before starting, you'll have baseline imaging scans and lab work. During treatment, you'll come for visits to receive trilaciclib followed by docetaxel chemotherapy, and have regular blood tests to monitor your blood cell counts and side effects. You'll also have imaging scans every 6 weeks to check how your cancer is responding. The study team will closely track any blood-related side effects and infections.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China